Thomas K. Equels Acquires 83,334 Shares of AIM ImmunoTech Inc. (NYSE:AIM) Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels purchased 83,334 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were purchased at an average cost of $0.12 per share, with a total value of $10,000.08. Following the completion of the purchase, the chief executive officer now owns 1,764,029 shares in the company, valued at $211,683.48. This represents a 4.96 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AIM ImmunoTech Price Performance

Shares of NYSE:AIM opened at $0.13 on Thursday. AIM ImmunoTech Inc. has a one year low of $0.11 and a one year high of $0.62. The stock has a fifty day moving average of $0.18 and a 200-day moving average of $0.23. The company has a market capitalization of $9.04 million, a PE ratio of -0.28 and a beta of 0.41. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their price target on AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Tuesday, December 10th.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).